Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methylnaltrexone Progenics.

Fabrizio De Ponti1

  • 1Department of Pharmacology, University of Bologna, Italy. deponti@biocfarm.unibo.it

Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Major Adverse Cardiac Events with Ondansetron: The Role of Observational Evidence to Inform Actionable Safer Prescribing in Cardio-Oncology.

Clinical pharmacology and therapeutics·2026
Same author

Learning planetary health through international & interprofessional education: a qualitative study of student reflections.

Medical education online·2026
Same author

Apixaban, direct oral anticoagulants and psychiatric events: Innocent bystander or true safety signal?

Journal of affective disorders·2026
Same author

Future-proofing medicine for a world of volatility, uncertainty, complexity, and ambiguity.

Academic medicine : journal of the Association of American Medical Colleges·2026
Same author

The use of generic versus brand names in (clinical) pharmacology education across Europe: a cross-sectional survey.

European journal of clinical pharmacology·2026
Same author

Anticancer drugs and depression through the lens of disproportionality analysis: unveiling underlying confounders and tips for prescribers.

Journal of affective disorders·2026
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Methylnaltrexone (MNTX) is an opioid antagonist being developed to treat opioid-induced constipation and post-operative bowel dysfunction. Clinical trials are underway to evaluate its efficacy and safety in managing these common side effects of opioid pain therapy.

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Oncology

Background:

  • Opioid pain therapy often causes gastrointestinal side effects like constipation and bowel dysfunction.
  • Methylnaltrexone (MNTX) is a peripherally acting opioid antagonist developed to counteract these effects.
  • Progenics Pharmaceuticals holds exclusive worldwide rights to MNTX, licensed from UR Labs and the University of Chicago.

Purpose of the Study:

  • To evaluate the safety and efficacy of methylnaltrexone (MNTX) for treating opioid-induced constipation.
  • To assess MNTX's potential in managing post-operative bowel dysfunction.
  • To advance MNTX through clinical trial phases for regulatory approval.

Main Methods:

  • Phase II clinical trials are being conducted to assess sc MNTX.

Related Experiment Videos

  • A double-blind, randomized study in cancer patients focuses on opioid-induced constipation.
  • Phase IIb trials are initiating for opioid-induced constipation and post-operative bowel dysfunction.

    • Main Results:

    • Methylnaltrexone (MNTX) is currently in Phase II clinical trials.
    • Phase III studies were anticipated to commence in 2002.
    • Initiation of Phase IIb trials for opioid-induced constipation and post-operative bowel dysfunction occurred in February 2002.

    Conclusions:

    • Methylnaltrexone (MNTX) shows promise as a treatment for opioid-related gastrointestinal side effects.
    • Ongoing clinical trials are crucial for establishing MNTX's therapeutic role.
    • Further research will determine MNTX's effectiveness in diverse patient populations and conditions.